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OBJECTIVES: Previous research has shown that untreated
insomnia has signiﬁcant direct and indirect burden. The lifetime
prevalence of major depressive disorder (MDD) is more than
17%, with up to 80% reporting comorbid insomnia. The
purpose of this study was to estimate the economic burden of
comorbid untreated insomnia within an adult depressed popula-
tion. METHODS: A large managed care claims database was
used to identify MDD subjects (18 to 64 years) anytime between
January 1, 1998 to November 30, 2007 using MDD-speciﬁc
ICD-9-CM diagnoses. Depressed insomniacs were selected from
this cohort using insomnia-speciﬁc ICD-9-CM codes/hypnotic-
use. Direct costs were compared with a 1:1 matched control
group that had depression and no insomnia vs. depressed-
insomniacs twelve-months prior to initiating insomnia treatment/
diagnosis. Total direct costs included inpatient, outpatient, ER
and drug costs. Multivariate regression analyses were conducted
to control for factors that were different even after matching.
Cost outcomes were analyzed using log-transformation and then
retransformed to their original scale after applying smearing
factor. All statistical tests were conducted using SAS 9.1.
RESULTS: A total of 41,594 controls were matched to 41,594
depressed-insomniacs on demographic characteristics, index-
date, antidepressant use, plan type, and region using propensity-
scoring technique. Depressed-insomniacs had statistically greater
(p < 0.01) total outpatient visits 9.24 (SD = 10.14) vs control
7.92 (SD = 8.42); depression-related visits 4.32 (SD = 8.33) vs
control 2.36 (SD = 5.32); and antidepressant prescriptions 5.28
(SD = 5.92) vs control 4.71 (SD = 5.27). Overall total direct costs
for depressed-insomniacs were signiﬁcantly (p < 0.001) higher
than controls ($6,772 vs. $5,644) after matching and controlling
for differences in age, location, plan-type, index year, and comor-
bidity patterns. The $1128 difference in average medical expen-
diture reﬂected the estimate of direct cost of untreated insomnia
in adult depressed population. CONCLUSIONS:Untreated
insomnia within an adult comorbid depressed population is asso-
ciated with signiﬁcant direct costs. Future research needs to
determine whether treating comorbid-insomnia with MDD
population is cost-effective.
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OBJECTIVES: Previous research has shown that untreated
insomnia within the elderly has signiﬁcant economic burden. The
lifetime prevalence of major depressive disorder (MDD) is more
than 17%, of which up to 80% have comorbid insomnia. The
purpose of this study was to estimate the economic burden of
untreated insomnia within an elderly comorbid depressed popu-
lation. METHODS: A large managed care claims database was
used to identify elderly MDD subjects between January 1, 1998
to November 30, 2007 using MDD-speciﬁc ICD-9-CM codes.
Depressed insomniacs were selected from this cohort using
insomnia-speciﬁc ICD-9-CM codes/hypnotic-use. Direct costs
were compared with a 1:1 matched control group that had
depression and no insomnia vs. depressed-insomniacs twelve-
months prior to initiating insomnia treatment/diagnosis. Total
direct costs included inpatient, outpatient, ER and drug costs.
Multivariate regression analyses were conducted to control for
factors that were different even after matching. Cost outcomes
were log-transformed and then retransformed to their original
scale after applying smearing factor. All statistical tests were
conducted using SAS 9.1. RESULTS: A total of 2900 controls
were matched to 2900 depressed-insomniacs on demographic
characteristics, index-date, antidepressant use, plan type,
and region using propensity-scoring technique. Depressed-
insomniacs had higher (p < 0.001) total outpatient visits 11.20
(SD = 10.32) vs control 8.71 (SD = 7.32); depression-related
visits 4.05 (SD = 8.41) vs control 1.70 (SD = 3.27);
antidepressant-use 3.39 (SD = 5.18) vs control 2.87 (SD = 4.51).
Overall total direct costs for depressed-insomniacs were signiﬁ-
cantly (p < 0.001) higher than controls ($9835 vs. $8384) after
matching and controlling for differences in age, location, plan-
type, index year, and comorbidity patterns. The $1451 difference
in average medical expenditure per-subject reﬂected the estimate
of direct cost of untreated insomnia in an elderly depressed
population. CONCLUSIONS: Untreated insomnia within an
elderly comorbid depressed population is associated with signiﬁ-
cant direct costs. Future research needs to determine prevalence
and cost-effectiveness of treating comorbid insomnia within this
population.
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OBJECTIVES: To analyse the economic impact of one-year
health care and non-health care resources utilization by patients
with Alzheimer disease (AD) under usual medical practice con-
ditions in Spain. METHODS: A one-year, prospective, natural-
istic, multicentre cohort study was designed to recruit treated
patients with mild, moderate to severe and severe AD according
to CDR: the ECO study. Health care resources included all kind
of medical visits, drugs and concomitant treatments, comple-
mentary tests, institutionalization and home-nursing facilities’
use. Non-health care resources included inventory materials,
consumables, professional and non-professional carers’ time of
care and supervision. Results were analysed according to
patients’ socio-demographic data, degree of AD (CDR; MMSE
and BDRS), overall health status (HUI3), and to variables inher-
ent to the main carer including hours of care and supervision
and health status (HUI3) and stress (Zarit). RESULTS: A total
of 560 patients with possible/probable AD by DSM-IV-
NINCDS-ADRDA criteria were included in the study; 68%
women, 77  6 years old, 29% treatment naïve. Monthly mean
cost was €1,078 (€12,936 patient/ year), increasing by 9.4% at
the end of the study from a baseline cost of €993. By compo-
nents, non-health care costs (€760, 71% of total cost) decreased
€7 (0.8%) at the end of the year, while health care costs grew
€101/month (43.9%), mainly driven by the cost of drugs,
nursing home utilization and institutionalization. The 82% of
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the overall cost (€884) was not ﬁnanced by Social Security, and
the majority of this cost corresponded to caregiver associated
cost (salaries and productivity lost). The caregiver economical
burden represents 68% of the overall cost-of-illness. CONCLU-
SIONS: Monthly overall mean cost of AD was high in Spain
(€1078), More than 80% of the cost-of-illness is funded by the
own patient family, adding an economical burden to the suffer-
ing of these families.
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OBJECTIVES: International studies have reported that patients
with ADHD incur higher health care costs than persons without
this condition, but little is known about the direct medical costs
associated with ADHD in Germany. The present study aims at
ﬁlling this void. METHODS: Health care resource utilization
data for patients with a diagnosis of ADHD (F90.0 and/or F90.1)
were extracted from the Nordbaden claims database (for year
2003), covering the complete regional population insured by
Statutory Health Insurance SHI (2.238 million lives in 2003),
and were combined with SHI prescription data. Complete
datasets were available for 3,831 outpatients with ADHD and
for a randomly selected control group matched 1:1 by age and
gender. For costing, resource use was valued applying SHI acqui-
sition costs. RESULTS: The annual average expenditure (direct
medical costs borne by SHI) per patient was €650 versus €251 for
matched controls, with physician charges accounting for 68%
(€444 versus €170 for controls). All categories of costs were
higher for patients with ADHD by a factor of 2 to 5 versus
controls, an observation that was consistent across age and
gender deﬁned subgroups. Average expenditures per patient with
ADHD increased with age (age group <7 years, €520; 7–12 years,
€622; 13–19 years, €661; >20 years, €1147), primarily reﬂecting
higher medication costs. In contrast, average costs per control
person showed little change across age groups (at €269, €245,
€250, and €272, respectively). Among children and adolescents,
there were no substantial spending differences by gender. CON-
CLUSIONS: These data are likely underestimates of the total
expenditures attributable to ADHD since they do neither include
costs of inpatient treatment nor cost of ergotherapeutic interven-
tions, which will have to be addressed in future studies. They
provide, for the ﬁrst time, robust information from Germany on
the signiﬁcant ﬁnancial burden for the SHI attributable to
ADHD.
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The type of antipsychotic determines the efﬁcacy and the toler-
ability for the patient. Long acting depot formulations were
designed to increase patient adherence to treatment. The second
generation atypical antipsychotics and long-acting injectable ris-
peridone (LAIR) in particular are more costly than conventional
antipsychotics, but may improve outcome of treatment; hence,
reducing costs associated with schizophrenia. OBJECTIVES:
Firstly, to provide estimates of the economic impact of schizo-
phrenia in Germany and to illustrate the cost-drivers in the
disease. Secondly, to present ﬁndings from a literature search of
published cost-effectiveness analyses of second generation schizo-
phrenia treatment, with focus on depot treatment. METHODS:
Based on data from the German Federal Bureau of Statistics,
the costs of schizophrenia were estimated from a top-down
approach. Additionally, costs were illustrated from a bottom-up
prevalence approach, based on data from published literature. A
literature search, using PubMed, was conducted to ﬁnd cost-
effectiveness data. RESULTS: Using a top-down approach, total
cost of schizophrenia in Germany was estimated to €7298
million in 2004. Direct and indirect costs were estimated to
€2715 and €4583 million respectively. Hospital stays represented
the largest share of the direct costs while invalidity was the main
reason for indirect costs. From the bottom-up approach, the total
cost of schizophrenia was estimated to between €4,920 million
and €10,420 million per year. The review of available economic
models shows that LAIR has a substantial cost advantage and
has been demonstrated to be cost- effective compared to alterna-
tive treatments. CONCLUSIONS: Schizophrenia is associated
with high health care and societal costs. LAIR has the potential
to improving the outcome of treatment, e.g. compliance; hence,
lower the costs associated with schizophrenia. Longer trials in a
naturalistic setting and studies regarding patient satisfaction of
LAIR are however requested.
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OBJECTIVES: While the substantial economic burden of depres-
sion is well documented, less is known about the cost of depres-
sion by clinical severity levels. This study’s objective is to
document the health care resource utilization and costs by sever-
ity for patients with major depressive disorder (MDD).
METHODS: Using data from the National Comorbidity Survey-
Replication (NCS-R; n = 5692), respondents were categorized
into clinical severity categories (not clinically depressed, mild,
moderate, severe) using standard scales (CIDI/QIDS-SR). Out-
comes were measured over 12 months and included the preva-
lence of medical services and antidepressant use, the average
number of visits and days on antidepressants, the prevalence of
treatment adequacy, and medical and drug costs. Costs were
estimated by weighting utilization measures by unit costs
obtained for similar services used by depressed patients in a U.S.
privately insured claims database for the corresponding time
period (2000–2001). Outcomes were compared across depres-
sion severity groups using chi-square tests and regression models
that generated F statistics adjusted for demographics. RESULTS:
Among the 658 depressed respondents, 14.2% were mildly,
38.1% moderately and 47.7% severely depressed. Respondents
in the 3 groups shared similar demographic characteristics. There
was a signiﬁcant association between severity and the prevalence
of mental health services usage (20.8%, 27.9%, and 39.5%
respectively, p < 0.01) and the average number of mental health
practitioner visits. The use of antidepressants also increased with
depression severity (19.8%, 29.8%, and 40.2% respectively, p <
0.05). Similarly, the adequacy of mental health services increased
with depression severity (8.9%, 12.1%, and 21.3% respectively,
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